Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein. / Salanti, Ali; Clausen, Thomas M; Agerbæk, Mette Ø; Al Nakouzi, Nader; Dahlbäck, Madeleine; Oo, Htoo Z; Lee, Sherry; Gustavsson, Tobias; Rich, Jamie R; Hedberg, Bradley J; Mao, Yang; Barington, Line; Pereira, Marina A; LoBello, Janine; Endo, Makoto; Fazli, Ladan; Soden, Jo; Wang, Chris K; Sander, Adam F; Dagil, Robert; Thrane, Susan; Holst, Peter J; Meng, Le; Favero, Francesco; Weiss, Glen J; Nielsen, Morten A; Freeth, Jim; Nielsen, Torsten O; Zaia, Joseph; Tran, Nhan L; Trent, Jeff; Babcook, John S; Theander, Thor G; Sorensen, Poul H; Daugaard, Mads.

In: Cancer Cell, Vol. 28, No. 4, 2015, p. 500-14.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Salanti, A, Clausen, TM, Agerbæk, MØ, Al Nakouzi, N, Dahlbäck, M, Oo, HZ, Lee, S, Gustavsson, T, Rich, JR, Hedberg, BJ, Mao, Y, Barington, L, Pereira, MA, LoBello, J, Endo, M, Fazli, L, Soden, J, Wang, CK, Sander, AF, Dagil, R, Thrane, S, Holst, PJ, Meng, L, Favero, F, Weiss, GJ, Nielsen, MA, Freeth, J, Nielsen, TO, Zaia, J, Tran, NL, Trent, J, Babcook, JS, Theander, TG, Sorensen, PH & Daugaard, M 2015, 'Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein', Cancer Cell, vol. 28, no. 4, pp. 500-14. https://doi.org/10.1016/j.ccell.2015.09.003

APA

Salanti, A., Clausen, T. M., Agerbæk, M. Ø., Al Nakouzi, N., Dahlbäck, M., Oo, H. Z., Lee, S., Gustavsson, T., Rich, J. R., Hedberg, B. J., Mao, Y., Barington, L., Pereira, M. A., LoBello, J., Endo, M., Fazli, L., Soden, J., Wang, C. K., Sander, A. F., ... Daugaard, M. (2015). Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein. Cancer Cell, 28(4), 500-14. https://doi.org/10.1016/j.ccell.2015.09.003

Vancouver

Salanti A, Clausen TM, Agerbæk MØ, Al Nakouzi N, Dahlbäck M, Oo HZ et al. Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein. Cancer Cell. 2015;28(4):500-14. https://doi.org/10.1016/j.ccell.2015.09.003

Author

Salanti, Ali ; Clausen, Thomas M ; Agerbæk, Mette Ø ; Al Nakouzi, Nader ; Dahlbäck, Madeleine ; Oo, Htoo Z ; Lee, Sherry ; Gustavsson, Tobias ; Rich, Jamie R ; Hedberg, Bradley J ; Mao, Yang ; Barington, Line ; Pereira, Marina A ; LoBello, Janine ; Endo, Makoto ; Fazli, Ladan ; Soden, Jo ; Wang, Chris K ; Sander, Adam F ; Dagil, Robert ; Thrane, Susan ; Holst, Peter J ; Meng, Le ; Favero, Francesco ; Weiss, Glen J ; Nielsen, Morten A ; Freeth, Jim ; Nielsen, Torsten O ; Zaia, Joseph ; Tran, Nhan L ; Trent, Jeff ; Babcook, John S ; Theander, Thor G ; Sorensen, Poul H ; Daugaard, Mads. / Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein. In: Cancer Cell. 2015 ; Vol. 28, No. 4. pp. 500-14.

Bibtex

@article{fa120af3843f41ce90f0013c5c9239a3,
title = "Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein",
abstract = "Plasmodium falciparum engineer infected erythrocytes to present the malarial protein, VAR2CSA, which binds a distinct type chondroitin sulfate (CS) exclusively expressed in the placenta. Here, we show that the same CS modification is present on a high proportion of malignant cells and that it can be specifically targeted by recombinant VAR2CSA (rVAR2). In tumors, placental-like CS chains are linked to a limited repertoire of cancer-associated proteoglycans including CD44 and CSPG4. The rVAR2 protein localizes to tumors in vivo and rVAR2 fused to diphtheria toxin or conjugated to hemiasterlin compounds strongly inhibits in vivo tumor cell growth and metastasis. Our data demonstrate how an evolutionarily refined parasite-derived protein can be exploited to target a common, but complex, malignancy-associated glycosaminoglycan modification.",
author = "Ali Salanti and Clausen, {Thomas M} and Agerb{\ae}k, {Mette {\O}} and {Al Nakouzi}, Nader and Madeleine Dahlb{\"a}ck and Oo, {Htoo Z} and Sherry Lee and Tobias Gustavsson and Rich, {Jamie R} and Hedberg, {Bradley J} and Yang Mao and Line Barington and Pereira, {Marina A} and Janine LoBello and Makoto Endo and Ladan Fazli and Jo Soden and Wang, {Chris K} and Sander, {Adam F} and Robert Dagil and Susan Thrane and Holst, {Peter J} and Le Meng and Francesco Favero and Weiss, {Glen J} and Nielsen, {Morten A} and Jim Freeth and Nielsen, {Torsten O} and Joseph Zaia and Tran, {Nhan L} and Jeff Trent and Babcook, {John S} and Theander, {Thor G} and Sorensen, {Poul H} and Mads Daugaard",
note = "Copyright {\textcopyright} 2015 Elsevier Inc. All rights reserved.",
year = "2015",
doi = "10.1016/j.ccell.2015.09.003",
language = "English",
volume = "28",
pages = "500--14",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "4",

}

RIS

TY - JOUR

T1 - Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein

AU - Salanti, Ali

AU - Clausen, Thomas M

AU - Agerbæk, Mette Ø

AU - Al Nakouzi, Nader

AU - Dahlbäck, Madeleine

AU - Oo, Htoo Z

AU - Lee, Sherry

AU - Gustavsson, Tobias

AU - Rich, Jamie R

AU - Hedberg, Bradley J

AU - Mao, Yang

AU - Barington, Line

AU - Pereira, Marina A

AU - LoBello, Janine

AU - Endo, Makoto

AU - Fazli, Ladan

AU - Soden, Jo

AU - Wang, Chris K

AU - Sander, Adam F

AU - Dagil, Robert

AU - Thrane, Susan

AU - Holst, Peter J

AU - Meng, Le

AU - Favero, Francesco

AU - Weiss, Glen J

AU - Nielsen, Morten A

AU - Freeth, Jim

AU - Nielsen, Torsten O

AU - Zaia, Joseph

AU - Tran, Nhan L

AU - Trent, Jeff

AU - Babcook, John S

AU - Theander, Thor G

AU - Sorensen, Poul H

AU - Daugaard, Mads

N1 - Copyright © 2015 Elsevier Inc. All rights reserved.

PY - 2015

Y1 - 2015

N2 - Plasmodium falciparum engineer infected erythrocytes to present the malarial protein, VAR2CSA, which binds a distinct type chondroitin sulfate (CS) exclusively expressed in the placenta. Here, we show that the same CS modification is present on a high proportion of malignant cells and that it can be specifically targeted by recombinant VAR2CSA (rVAR2). In tumors, placental-like CS chains are linked to a limited repertoire of cancer-associated proteoglycans including CD44 and CSPG4. The rVAR2 protein localizes to tumors in vivo and rVAR2 fused to diphtheria toxin or conjugated to hemiasterlin compounds strongly inhibits in vivo tumor cell growth and metastasis. Our data demonstrate how an evolutionarily refined parasite-derived protein can be exploited to target a common, but complex, malignancy-associated glycosaminoglycan modification.

AB - Plasmodium falciparum engineer infected erythrocytes to present the malarial protein, VAR2CSA, which binds a distinct type chondroitin sulfate (CS) exclusively expressed in the placenta. Here, we show that the same CS modification is present on a high proportion of malignant cells and that it can be specifically targeted by recombinant VAR2CSA (rVAR2). In tumors, placental-like CS chains are linked to a limited repertoire of cancer-associated proteoglycans including CD44 and CSPG4. The rVAR2 protein localizes to tumors in vivo and rVAR2 fused to diphtheria toxin or conjugated to hemiasterlin compounds strongly inhibits in vivo tumor cell growth and metastasis. Our data demonstrate how an evolutionarily refined parasite-derived protein can be exploited to target a common, but complex, malignancy-associated glycosaminoglycan modification.

U2 - 10.1016/j.ccell.2015.09.003

DO - 10.1016/j.ccell.2015.09.003

M3 - Journal article

C2 - 26461094

VL - 28

SP - 500

EP - 514

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 4

ER -

ID: 147243458